Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer

被引：0

作者：

I.-M. Launonen

N. Lyytikäinen

J. Casado

E. A. Anttila

A. Szabó

U.-M. Haltia

C. A. Jacobson

J. R. Lin

Z. Maliga

B. E. Howitt

K. C. Strickland

S. Santagata

K. Elias

A. D. D’Andrea

P. A. Konstantinopoulos

P. K. Sorger

A. Färkkilä

机构：

[1] University of Helsinki,Research Program in Systems Oncology

[2] Helsinki University Hospital,Department of Obstetrics and Gynecology

[3] Harvard Medical School,Laboratory of Systems Pharmacology

[4] Stanford University School of Medicine,Department of Pathology

[5] Duke University Medical Center,Department of Pathology

[6] Brigham and Women’s Hospital,Department of Pathology

[7] Brigham and Women’s Hospital,Department of Obstetrics and Gynecology and Reproductive Biology

[8] Harvard Medical School,Dana

[9] Harvard Medical School,Farber Cancer Institute, Brigham and Women’s Hospital

[10] iCAN Digital Precision Cancer Medicine Flagship,Ludwig Center for Cancer Research at Harvard

来源：

Nature Communications | / 13卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The majority of high-grade serous ovarian cancers (HGSCs) are deficient in homologous recombination (HR) DNA repair, most commonly due to mutations or hypermethylation of the BRCA1/2 genes. We aimed to discover how BRCA1/2 mutations shape the cellular phenotypes and spatial interactions of the tumor microenvironment. Using a highly multiplex immunofluorescence and image analysis we generate spatial proteomic data for 21 markers in 124,623 single cells from 112 tumor cores originating from 31 tumors with BRCA1/2 mutation (BRCA1/2mut), and from 13 tumors without alterations in HR genes. We identify a phenotypically distinct tumor microenvironment in the BRCA1/2mut tumors with evidence of increased immunosurveillance. Importantly, we report a prognostic role of a proliferative tumor-cell subpopulation, which associates with enhanced spatial tumor-immune interactions by CD8+ and CD4 + T-cells in the BRCA1/2mut tumors. The single-cell spatial landscapes indicate distinct patterns of spatial immunosurveillance with the potential to improve immunotherapeutic strategies and patient stratification in HGSC.

引用

共 53 条

[1]

Reid BM(2017)Epidemiology of ovarian cancer: A review Cancer. Biol. Med. 14 9-32

[2]

Permuth JB(2019)High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints Int. J. Mol. Sci. 20 952-296

[3]

Sellers TA(2018)Ovarian cancer statistics, 2018 CA. Cancer. J. Clin. 68 284-615

[4]

Lisio MA(2011)Integrated genomic analyses of ovarian carcinoma Nature. 474 609-13598

[5]

Fu L(2020)Exploiting the prevalence of homologous recombination deficiencies in high-grade serous ovarian cancer Cancers. (Basel) 12 1206-407

[6]

Goyeneche A(2016)Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer Oncotarget. 7 13587-15631

[7]

Gao ZH(2021)Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy Cancer Disc. 11 384-17

[8]

Telleria C(2017)DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells Nat. Commun. 8 15621-402

[9]

Torre LA(2020)Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer Nat. Commun. 11 10-9181

[10]

Bouberhan S(2017)The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer Oncotarget. 8 393-434

← 1 2 3 4 5 6 →